Siga Technologies INC Deferred Foreign Income Tax Expense (Benefit)
Siga Technologies INC (SIGA) reported Deferred Foreign Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-03-10
- Siga Technologies INC deferred foreign income tax expense (benefit) for fiscal 2025 was $0.00.
- Siga Technologies INC deferred foreign income tax expense (benefit) for fiscal 2024 was $0.00.
- Siga Technologies INC deferred foreign income tax expense (benefit) for fiscal 2023 was $0.00.
- Siga Technologies INC deferred foreign income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-10 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-10 |
| 2023-12-31 | $0.00 10-K · filed 2026-03-10 |
| 2022-12-31 | $0.00 10-K · filed 2025-03-11 |
| 2021-12-31 | $0.00 10-K · filed 2024-03-12 |
| 2020-12-31 | $0.00 10-K · filed 2023-03-02 |
| 2019-12-31 | $0.00 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |